Year: 2022
Type: article
Abstract: Lung cancer is the leading cause of cancer deaths worldwide. Especially, non- small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. Oncogenic mutations in the Kirsten rat sarcoma viral oncogene (KRAS) gene play an important role in tumorigenesis and are mutated in approximately 30% of all NSCLC patients. KRAS functions by propagating signal transduction pathways upon activation and is involved in cell differentiation and cell growth. Mutations of the KRAS gene result in uncontrolled proliferation and development of cancer. NSCLCpatients with KRAS mutation respond poorly to chemotherapy and resistance to EGFR inhibitors. However, Immune checkpoint inhibitors show favourable outcomes for KRAS mutant patients, with an improved overall survival. Sotorasib (AMG510), the first drug-targeting KRAS (G12C) gene mutation has been approved in 2021 for KRAS mutated NSCLC (First-in-class), brings hope to the many patients who carry this mutation. In this article, role of oncogenic KRAS in prognosis and treatment of KRAS- mutant NSCLC are reviewed
Source: Thai cancer journal
Author: Wongsirisin, Pattama
Institution: National Cancer Institute of Thailand
Language: Thai
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7220551244
